The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations

• Published in: World neurosurgery 2024-01, Vol.181, p.e133-e153
• Main Authors: Mehkri, Yusuf, Windermere, Sonora Andromeda, Still, Megan E.H., Yan, Sandra C., Goutnik, Michael, Melnick, Kaitlyn, Doonan, Bently, Ghiaseddin, Ashley P., Rahman, Maryam
• Format: Article
• Language: English
• Subjects: Brain metastases; Brain Neoplasms - radiotherapy; Combined Modality Therapy; Humans; Immune checkpoint blockade; Immune checkpoint inhibitor; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Necrosis; Radiosurgery - adverse effects; Retrospective Studies; Stereotactic radiosurgery
• ISSN: 1878-8750; 1878-8769; 1878-8769
• DOI: 10.1016/j.wneu.2023.09.042

Immune checkpoint inhibitors (ICIs) have shown growing promise in the treatment of brain metastases, especially combined with stereotactic radiosurgery (SRS). The combination of ICIs with SRS has been studied for efficacy as well as increasing radiation necrosis risks. In this review, we compare clinical outcomes of radiation necrosis, intracranial control, and overall survival between patients with brain metastases treated with either SRS alone or SRS-ICI combination therapy. A literature search of PubMed, Scopus, Embase, Web of Science, and Cochrane was performed in May 2023 for articles comparing the safety and efficacy of SRS/ICI versus SRS-alone for treating brain metastases. The search criteria identified 1961 articles, of which 48 met inclusion criteria. Combination therapy with SRS and ICI does not lead to significant increases in incidence of radiation necrosis either radiographically or symptomatically. Overall, no difference was found in intracranial control between SRS-alone and SRS-ICI combination therapy. Combination therapy is associated with increased median overall survival. Notably, some comparative studies observed decreased neurologic deaths, challenging presumptions that improved survival is due to greater systemic control. The literature supports SRS-ICI administration within 4 weeks of another for survival but remains inconclusive, requiring further study for other outcome measures. Combination SRS-ICI therapy is associated with significant overall survival benefit for patients with brain metastases without significantly increasing radiation necrosis risks compared to SRS alone. Although intracranial control rates appear to be similar between the 2 groups, timing of treatment delivery may improve control rates and demands further study attention.